Michael A. Tortorici, PharmD, PhD

Vice President, Translational Medicine & Clinical Pharmacology
Mineralys Therapeutics, Inc.

Poster(s):

• 038: Lorundrostat Concentration-QTc Results from the First-in-Human Study in Healthy Participants Demonstrate Lack of Relevant Effect & Replaces the Thorough QT Study
  Sunday, September 8, 2024

  5:00 PM – 7:00 PM ET